Home Our Approach Pipeline

Technology

Technology Overview Technology Access Program (TAP)

About Us Careers

Contact

Report a Side Effect Get in touch

News

All Eikon Stories In the News Press Releases Scientific Papers

/

/

Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets

Perlmutter named CEO of Eikon, a biotech with $148M to apply Nobel-winning tech to undruggable targets

PAGES

Home Pipeline Technology About Us Careers Contact Report a Side Effect News

© 2023 Eikon Therapeutics, Inc. All rights reserved. Privacy Policy